FVR Suomen rokotetutkimus Oy
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
Research at Seinäjoen Rokotetutkimusklinikka focuses on preventing serious bacterial infections in newborns by testing vaccines that target maternal and infant immunity. The primary effort evaluates a Group B streptococcus vaccine to protect both mother and child.
- Group B streptococcus vaccine safety in pregnancy
- Induction of anti‑CPS IgG antibodies for protection
- Maternal immunization to reduce newborn disease
- Monovalent pneumococcal conjugate safety and immunogenicity in toddlers
FVR Suomen rokotetutkimus Oy supports these studies with a dedicated team of investigators.
Respiratory Tract Diseases
The clinic is investigating new strategies to reduce severe lower‑respiratory infections caused by RSV in infants and high‑risk children. A key trial compares the investigational monoclonal antibody MK‑1654 with the standard treatment palivizumab.
- RSV vaccine efficacy in infants and toddlers
- Comparison of MK‑1654 with palivizumab for safety and efficacy
- Incidence of medically attended lower respiratory infections
- Safety profile of RSV monoclonal antibodies across seasons
The research team at Seinäjoen Rokotetutkimusklinikka aims to lower hospitalizations due to severe respiratory disease.
Virus Diseases
Broader viral disease research at the site includes evaluating vaccine candidates that aim to prevent viral respiratory illnesses in early childhood. These studies address challenges related to virus diseases by measuring protection and safety outcomes.
- Assessment of vaccine‑induced protection against viral respiratory pathogens
- Safety monitoring of viral vaccine candidates in toddlers
- Immunogenicity profiling of novel viral antigens
- Evaluation of viral load reduction after vaccination
Ongoing work contributes to global efforts to control common viral infections in pediatric populations.
Immune system processes
Studies emphasize the underlying immune system processes that drive protection, measuring antibody responses and safety outcomes across maternal and pediatric vaccine trials. Researchers track immunogenicity markers to predict vaccine effectiveness.
- Immunogenicity assessments of maternal vaccines
- Antibody level predictions for protection against early‑onset disease
- Safety monitoring of vaccine candidates in infants and pregnant women
- Evaluation of immune response biomarkers across study arms
The collaborative environment at FVR Suomen rokotetutkimus Oy enables detailed analysis of how the immune system responds to new preventive therapies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Pfizer Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in FVR Suomen rokotetutkimus Oy
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | Merck Sharp & Dohme LLC | Phase IV | Not Recruiting | Nov 2022 | Feb 2024 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 534 | 1 | Unknown | 2024-08-09 | 2024-08-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.